Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
44
UCBJY Quote, Financials, Valuation and Earnings
Last price:
$144.05
Seasonality move
:
6.51%
Day range:
$142.55 - $148.85
52-week range:
$71.16 - $151.76
Dividend yield:
0.55%
P/E ratio:
38.71x
P/S ratio:
7.52x
P/B ratio:
9.66x
Volume:
17.5K
Avg. volume:
27.4K
1-year change:
46.75%
Market cap:
$54.7B
Revenue:
$6.7B
EPS (TTM):
$3.81
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, UCB SA has -- downside to fair value with a price target of -- per share.
UCBJY vs. S&P 500
-
Over the past 5 trading days, UCB SA has overperformed the S&P 500 by 3.02% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
UCB SA does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
UCB SA has grown year-over-year revenues for 0 quarters straight. In the most recent quarter UCB SA reported revenues of --.
Earnings Growth
-
UCB SA has grown year-over-year earnings for 0 quarters straight. In the most recent quarter UCB SA reported earnings per share of --.
Enterprise value:
54.5B
EV / Invested capital:
--
Price / LTM sales:
7.52x
EV / EBIT:
41.04x
EV / Revenue:
7.32x
PEG ratio (5yr expected):
0.13x
EV / Free cash flow:
46.74x
Price / Operating cash flow:
47.99x
Enterprise value / EBITDA:
26.99x
Gross Profit (TTM):
$5.2B
Return On Assets:
7.93%
Net Income Margin (TTM):
19.43%
Return On Equity:
13.88%
Return On Invested Capital:
10.75%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2010-12-31 | 2011-12-31 | 2012-12-31 | 2011-12-31 | 2012-12-31 | |
| Income Statement | ||||||
| Revenue | $4.3B | $4.5B | $4.5B | -- | -- | |
| Gross Profit | $2.9B | $3.1B | $3.1B | -- | -- | |
| Operating Income | $620.6M | $591.1M | $572.7M | -- | -- | |
| EBITDA | $958M | $933.3M | $869.2M | -- | -- | |
| Diluted EPS | $0.33 | $0.83 | $0.90 | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $3.5B | $3.4B | $3.3B | $3.6B | $6.2B | |
| Total Assets | $15.5B | $17B | $16.7B | $16.8B | $20.2B | |
| Current Liabilities | $2.8B | $3B | $2.9B | $3B | $4.6B | |
| Total Liabilities | $6.4B | $7.7B | $6.9B | $7.2B | $8.8B | |
| Total Equity | $9.1B | $9.3B | $9.8B | $9.6B | $11.4B | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-12-08 | 2024-12-08 | 2024-12-08 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
UCBJY
Sector
Market Cap
$54.7B
$28.5M
Price % of 52-Week High
94.92%
51.44%
Dividend Yield
0.55%
0%
Shareholder Yield
1.15%
-1.33%
1-Year Price Total Return
46.75%
-20.32%
Beta (5-Year)
0.675
0.520
Dividend yield:
0.55%
Annualized payout:
$0.73
Payout ratio:
-19.96%
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$139.57
200-day SMA
Buy
Level
$108.91
Bollinger Bands (100)
Buy
Level
111.17 - 140.45
Chaikin Money Flow
Buy
Level
2.8M
20-day SMA
Buy
Level
$135.17
Relative Strength Index (RSI14)
Buy
Level
65.06
ADX Line
Buy
Level
19.17
Williams %R
Neutral
Level
-27.2263
50-day SMA
Buy
Level
$138.29
MACD (12, 26)
Buy
Level
1.90
25-day Aroon Oscillator
Buy
Level
92
On Balance Volume
Neutral
Level
2.8M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.1008)
Buy
CA Score
(Annual)
Level (0.1406)
Buy
Beneish M-Score
(Annual)
Level (-2.3834)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-2.0121)
Buy
Piotroski F Score
(Annual)
Level (8)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
UCB SA engages in the research and development of biopharmaceuticals products. It offers medicinal products such as briviact, keppra, vimpat, neupro, cimzia, nootropil, xyrem, xyzal, and zyrtec. The company was founded by Emmanuel Janssen on January 18, 1928 and is headquartered in Brussels, Belgium.
Stock Forecast FAQ
In the current month, UCBJY has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The UCBJY average analyst price target in the past 3 months is --.
-
Where Will UCB SA Stock Be In 1 Year?
According to analysts, the consensus estimate is that UCB SA share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About UCB SA?
Analysts are divided on their view about UCB SA share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that UCB SA is a Sell and believe this share price will rise from its current level to --.
-
What Is UCB SA's Price Target?
The price target for UCB SA over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is UCBJY A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for UCB SA is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of UCBJY?
You can purchase shares of UCB SA via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase UCB SA shares.
-
What Is The UCB SA Share Price Today?
UCB SA was last trading at $144.05 per share. This represents the most recent stock quote for UCB SA. Yesterday, UCB SA closed at $144.05 per share.
-
How To Buy UCB SA Stock Online?
In order to purchase UCB SA stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
Get UCBJY Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
UCBJY
Sector
P/E ratio
38.71x
23.75x
PEG ratio
0.13x
-0.01x
P/B ratio
9.66x
1.83x
Price / LTM sales
7.52x
1.60x
Growth Metrics
UCBJY
Sector
Revenue growth
--
4.85%
Earnings growth
--
11.11%
Revenue (5-year growth)
3.89%
6.45%
Earnings forecast
--
-$0.20
Profitability
UCBJY
Sector
Profitability FY 2024
$4.5B
$3.6M
Return on invested capital
10.75%
-30.98%
Return on assets
7.93%
-27.62%
Return on equity
13.88%
-36.69%
Earnings Date
Last Earnings Date
Jul
31
Next Earnings Date
Feb
25
Estimated Next Earnings Date
Oct
30
Balance Sheet
UCBJY
Sector
Total cash
$2.4B
$27.2M
Short term investments
$191.5M
$25.7M
Total assets
$18B
$79.7M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 6
SMX (Security Matters) Plc [SMX] is up 134.09% over the past day.
Buy
62
PRAX alert for Dec 6
Praxis Precision Medicines, Inc. [PRAX] is up 30.47% over the past day.
Sell
13
PSN alert for Dec 6
Parsons Corp. [PSN] is down 21.1% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
